<p>The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing, and to determine a minimal set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations on a minimal panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories in designing assays for PGx testing. When developing these recommendations, the Association for Molecular Pathology PGx Working Group considered the functional impact of the variant alleles, allele frequencies in multiethnic populations, the availability of reference materials, as well as other technical considerations with regard to PGx testing. The ultimate goal of this Working Group is to promote standardization of PGx gene/allele testing across clinical laboratories. This document is focused on clinical CYP2D6 PGx testing that may be applied to all cytochrome P450 2D6–metabolized medications. These recommendations are not meant to be interpreted as prescriptive but to provide a reference guide for clinical laboratories that may be either implementing PGx testing or reviewing and updating their existing platform.</p>

doi.org/10.1016/j.jmoldx.2021.05.013, hdl.handle.net/1765/136387
Journal of Molecular Diagnostics
Erasmus MC: University Medical Center Rotterdam

Victoria M. Pratt, Larisa H. Cavallari, Andria L. Del Tredici, Andrea Gaedigk, Houda Hachad, Yuan Ji, … Karen E. Weck. (2021). Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics (Vol. 23, pp. 1047–1064). doi:10.1016/j.jmoldx.2021.05.013